Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1Phase 3 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Primary Myelofibrosis 28Myeloproliferative Disorders 21Polycythemia Vera 16Thrombocythemia, Essential 7Neoplasms 7Pancreatic Neoplasms 6Multiple Myeloma 6Leukemia 6Hematologic Diseases 5Myelodysplastic Syndromes 4Graft vs Host Disease 4Colorectal Neoplasms 4Bone Marrow Diseases 4Thrombocytosis 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Leukemia, Myeloid, Acute 3Carcinoma, Non-Small-Cell Lung 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Prostatic Neoplasms 2Lymphoma 2Uveal Melanoma 1Thalassemia 1Recurrence 1Preleukemia 1Precancerous Conditions 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms by Histologic Type 1

Interventions

Methotrexate 6ruxolitinib 4ibrutinib 4Mycophenolic Acid 3Cyclosporine 3Transplantation Conditioning 2Tacrolimus 2Sirolimus 2Prednisone 2Methylprednisolone 2Cyclophosphamide 2Calcineurin Inhibitors 2thymoglobulin 1siplizumab 1remestemcel-l 1milatuzumab 1itacitinib 1eritoran 1axatilimab 1angiotensin I (1-7) 1Saline Solution 1Rituximab 1Radiotherapy 1Proto-Oncogene Proteins c-raf 1Photopheresis 1Peripheral Blood Stem Cell Transplantation 1Pentostatin 1Panobinostat 1KRN 7000 1Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Graft vs Host Disease × ruxolitinib × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT03774082 2025-12-11

REACH 5

Novartis

Phase 2 Completed
46 enrolled 21 charts
Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Incyte Corporation

Phase 3 Completed
330 enrolled 32 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT02953678 2021-11-24

A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

Incyte Corporation

Phase 2 Completed
71 enrolled 24 charts 1 FDA

Graft vs Host Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡